Definium Therapeutics (DFTX) Non-Current Assets (2021 - 2026)

Definium Therapeutics (DFTX) has reported Non-Current Assets for 6 consecutive years, with $20.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Assets fell 61.34% year-over-year to $20.7 million; the TTM figure through Mar 2026 stood at $138.5 million (up 20.45% YoY), while the FY2025 annual figure was $20.8 million, up 1.21% from the prior year.
• Non-Current Assets was little changed at $20.7 million in Q1 2026 per DFTX's latest filing, from $20.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $76.0 million in Q2 2025 and bottomed at $20.1 million in Q1 2024.
• Historically, Non-Current Assets has averaged $27.1 million across 5 years, with a median of $21.5 million in 2023.
• Annual changes were most pronounced in 2025 — Non-Current Assets surged 271.38% — and 2026, when it plunged 61.34%.
• Definium Therapeutics' Non-Current Assets stood at $23.9 million in 2022, then dropped by 13.66% to $20.7 million in 2023, then declined by 0.67% to $20.5 million in 2024, then rose by 1.21% to $20.8 million in 2025, then fell by 0.24% to $20.7 million in 2026.
• Business Quant data shows DFTX's Non-Current Assets at $20.7 million in Q1 2026, $20.8 million in Q4 2025, and $21.1 million in Q3 2025.